top of page
Clinical Stage I
ARV-102 shows strong brain penetration, broad LRRK2 degradation, and good tolerability in healthy volunteers—supporting its advance into Phase 1 trials for Parkinson’s disease.
Written by Arvinas, Inc. Featuring commentary from Dr. Noah Berkowitz
April 4, 2025
bottom of page